EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

On Tuesday, Coya Therapeutics, Inc. COYA announced the expansion of its investigational pipeline and advancement of COYA 303 for inflammatory diseases.

COYA 303 is an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous administration.

In a preclinical study, COYA 303 exhibited a dual immunomodulatory mechanism of action resulting in an additive/synergistic anti-inflammatory effect, which the Company believes was due to increased Treg function and suppressed pro-inflammatory myeloid cells and responder T cells. 

Also Read: EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Coya intends to publish the results of this study in a peer-reviewed publication in the first half of 2025 and has filed several patent applications to protect the compound. 

Coya intends to continue ongoing strategic discussions to advance COYA 303 through IND-enabling studies and into the clinic. Coya is initiating translational studies in partnership with a major academic university to support these efforts.

"COYA 303 is the most recent addition to Coya's investigational pipeline. We believe that while GLP-1 RAs may have monotherapy benefits in reducing inflammation, the unique anti-inflammatory signature of the combination of GLP-1 RA and COYA 301 is supportive of opportunities that may generate significant shareholder value for Coya and a potential strategic partner," stated CEO Arun Swaminathan.

In December, Coya Therapeutics announced that five of eight patients enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD).

The Alzheimer's Drug Discovery Foundation has awarded Coya $5 million to support the development of COYA 302 in FTD.

Price Action: COYA stock is up 8.55% at $5.84 during the premarket session at last check Tuesday.

Read Next:

• WE Fashion Taps Oracle Cloud For Global Retail Solutions: Details